The use of self-monitoring of blood glucose (SMBG) has been a standard of care for people with type 2 diabetes.This observational real-world study with a large health plan, a blood glucose meter company and a digital health solution was conducted virtually to evaluate the impact of the FDA-cleared One Touch Reveal Plus® app (OTRP) powered by Welldoc’s
BlueStar® on BG control through a pre-post study of glucose control, participant engagement, and health care utilization and cost.
Optimal management of people with type 2 diabetes often requires collaboration among healthcare providers and educators.Treatment plans require attention to a person’s behaviors related to self-monitoring, food choices, exercise, and medication taking. These patient data are frequently not available to the healthcare team, thus making coaching the patient and adjusting the treatment plan difficult. This study shows how the viewing of patient-generated health data enhances the clinician’s ability to modify the treatment plan.
Digital health applications have the potential to improve overall health status in people with diabetes.The purpose of this research was to build a predictive model that can predict which patients will persist in using the application, and which patients will experience improvement in blood glucose (BG) using BlueStar digital app as therapy.